- Home
- ALX vs SLN Comparison
ALX vs SLN Comparison
Compare ALX & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | SLN |
|---|---|---|
| Founded | 1928 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1994 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ALX | SLN |
|---|---|---|
| Price | $248.37 | $19.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $33.00 |
| AVG Volume (30 Days) | 24.1K | ★ 3.9M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 31.15 | N/A |
| Revenue | ★ $213,183,000.00 | $559,000.00 |
| Revenue This Year | $14.78 | N/A |
| Revenue Next Year | N/A | $130.93 |
| P/E Ratio | $7.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $201.28 | $4.19 |
| 52 Week High | $289.43 | $19.69 |
Technical Indicators
Market Signals| Indicator | ALX | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 53.43 | 79.34 |
| Support Level | $242.66 | $4.97 |
| Resistance Level | $251.32 | N/A |
| Average True Range (ATR) | 4.70 | 0.45 |
| MACD | 1.49 | 1.28 |
| Stochastic Oscillator | 85.65 | 99.86 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.